Roche Holding AG (RO)

386.20
-1.60(-0.41%)
  • Volume:
    18,674
  • Bid/Ask:
    386.20/386.80
  • Day's Range:
    383.40 - 388.40
Earnings results expected in 15 days

Roche Holding will announce its quarterly financial results in days. Traders should take this into account as the share price often fluctuates around this time period.

RO Overview

Prev. Close
387.8
Day's Range
383.4-388.4
Revenue
62.8B
Open
384.8
52 wk Range
341-439.2
EPS
17.85
Volume
18,674
Market Cap
309.38B
Dividend (Yield)
9.30
(2.40%)
Average Vol. (3m)
43,767
P/E Ratio
21.19
Beta
0.297
1-Year Change
0.73%
Shares Outstanding
801,094,291
Next Earnings Date
Oct 18, 2022
What is your sentiment on Roche Holding?
or
Market is currently closed. Voting is open during market hours.

Roche Holding AG News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Roche Holding AG Analysis

Roche Holding AG Company Profile

Roche Holding AG Company Profile

Employees
100920
  • Type:Equity
  • Market:Switzerland
  • ISIN:CH0012032113
  • S/N:1203211

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.

Read More

Analyst Price Target

Average376.25 (-2.58% Downside)
High450
Low300
Price386.2
No. of Analysts25
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellNeutralStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellSellStrong BuyNeutral
SummaryStrong SellStrong SellNeutralStrong BuyBuy
  • A large pharmaceutical company, by the name of R. , is pushing down the value of the Spanish company's Pharmamar share price through the funds Consonance Capital and Great Point Partners, so that the biotech company accepts its offer of more than 4500 million dollars.According to this pharma, Pharmamar's products have a great future in oncology and virology, and would be fully engaged in its search for new drugs.
    1
    • 13.11.2020. CHMP recommends EU approval of Roche’s Xofluza® (baloxavir marboxil) for the treatment of influenza. This CHMP recommendation brings patients with influenza one step closer to potentially benefiting from Xofluza’s oral one-dose regimen, setting adults and adolescents on the path to feeling better sooner compared to placebo,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We believe that access to effective antivirals for influenza, and particularly their use in the prophylactic setting, could help reduce the strain of the COVID-19 pandemic on healthcare systems in Europe.
      0
      • Just like Biolidics. they get approval for Covid19 tests kits in USA
        0
        • i dont know
          0
          • is the historical price adjusted for stock splits?
            0
            • i dont know
              0